| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
HeartBeam, Inc.
13D/A
BEAT · 42238H108
|
6.8% |
8/13/2026
Event 4/16/2026
|
||||
| Strome Mark E | 6.8% | |||||
| Strome Group, Inc. | 6.6% | |||||
| Strome Investment Management LP | 6.6% | |||||
| Strome Mezzanine Fund II, LP | 6.6% | |||||
|
Zivo Bioscience
13D/A
ZIVO · 98978N101
|
12.1% |
2/27/2026
Event 12/31/2025
|
||||
| Mark E. Strome | 12.1% | |||||
| Strome Group, Inc. | 7.1% | |||||
| Strome Investment Management, LP | 7.1% | |||||
| Strome Mezzanine Fund, LP | 0% | |||||
| Strome Mezzanine Fund II, LP | 6.8% | |||||
| Schedule 13G · 2 securities · passive | ||||||
|
Cue Biopharma, Inc.
13G/A
CUE · 22978P205
|
8.5%
Checked 5% or less
|
10/8/2026
Event 7/14/2026
|
||||
| Mark E. Strome | 8.5% | |||||
| Strome Group, Inc. | 8.5% | |||||
| Strome Investment Management, LP | 8.5% | |||||
| Strome Dynasty, LLC | 0.7% | |||||
| Strome Mezzanine Fund, LP | 0% | |||||
| Strome Mezzanine Fund II, LP | 7.8% | |||||
|
Cue Biopharma, Inc.
13G/A
CUE · 22978P106
|
4.99% |
5/16/2025
Event 11/14/2022
|
||||
| Mark E. Strome | 4.99% | |||||
| Strome Mezzanine Fund, LP | 0.1% | |||||
| Strome Mezzanine Fund II, LP | 4.4% | |||||
| Strome Dynasty, LLC. | 0.4% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.